Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Exelixis Inc (EXEL) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 4,846,840
  • Shares Outstanding, K 230,330
  • Annual Sales, $ 37,170 K
  • Annual Income, $ -169,740 K
  • 36-Month Beta 1.78
  • Price/Sales 130.39
  • Price/Book 121.71

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.04 +73.01%
on 11/03/16
17.74 -2.09%
on 12/02/16
+6.56 (+60.68%)
since 11/02/16
3-Month
10.04 +73.01%
on 11/03/16
17.74 -2.09%
on 12/02/16
+5.83 (+50.52%)
since 09/02/16
52-Week
3.55 +389.30%
on 03/17/16
17.74 -2.09%
on 12/02/16
+11.73 (+207.98%)
since 12/02/15

Most Recent Stories

More News
5 Top Performing Biotechnology Stocks of November

November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.

Exelixis (EXEL): Strong Industry, Solid Earnings Estimate Revisions

Exelixis (EXEL) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults

Sanofi (SNY) announced that the FDA has approved its once-daily injection, Soliqua 100/33

New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day

New Oriental Education & Technology Group, BJ’s Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day

Endo Reports Positive Cellulite Treatment Data on Xiaflex

Endo International plc (ENDP) announced positive data from a phase IIb study on Xiaflex

Shire Launches Cuvitru in U.S. for Primary Immunodeficiency

Shire plc (SHPG) announced the launch of Cuvitru in the U.S.

3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise

Will a Trump presidency trigger more M&A deals in the biotech sector?

Biotech Stocks Press Forward with Drug-Development Advancements

The biotech sector reacted positively to the election results based on high hopes there may be fewer drug pricing issues to deal with in the near future. The market for anti-cancer drug solutions specifically...

Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration

Bristol-Myers (BMY) and Enterome strike immuno-oncology collaboration focused on microbiome-derived biomarkers, drug targets and bioactive molecules.

Surging Earnings Estimates Signal Good News for Exelixis (EXEL)

Exelixis (EXEL) has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Support & Resistance

2nd Resistance Point 18.50
1st Resistance Point 17.93
Last Price 17.37
1st Support Level 16.61
2nd Support Level 15.86

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.